{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:46:44Z","timestamp":1791989204356,"version":"4.4.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.cca.2026.122892","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:33:22Z","timestamp":1791729202000},"page":"122892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Precision medicine in MASLD: Integrating genetics, multi-omics, and artificial intelligence for risk stratification and targeted therapy"],"prefix":"10.1016","volume":"594","author":[{"given":"Hiba Adnan Aziz Abu","family":"Omaima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba Salih","family":"Saihood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas Hasan","family":"Burhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiqar Adnan Azeez","family":"Aboomaima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Raoufinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.cca.2026.122892_bb0005","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.3350\/cmh.2024.0438","article-title":"Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease","volume":"31","author":"Caddeo","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0010","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2026.122892_bb0015","doi-asserted-by":"crossref","DOI":"10.18502\/abi.v2i1.16242","article-title":"A review of the therapeutic effects of polyphenols on non-alcoholic fatty liver disease: focus on oxidative stress","author":"Soleimani","year":"2024","journal-title":"Acta Biochimica Iranica"},{"issue":"5","key":"10.1016\/j.cca.2026.122892_bb0020","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s12325-021-01690-1","article-title":"Perspectives on precision medicine approaches to NAFLD diagnosis and management","volume":"38","author":"Lonardo","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.cca.2026.122892_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijsu.2020.05.062","article-title":"Current status of liver transplantation in Europe","volume":"82S","author":"Muller","year":"2020","journal-title":"Int. J. Surg."},{"issue":"3","key":"10.1016\/j.cca.2026.122892_bb0030","first-page":"133","article-title":"Recent advances in nanodelivery systems for polyphenols in metabolic dysfunction-associated steatotic liver disease (MASLD): an update","volume":"3","author":"Ghaffari","year":"2025","journal-title":"Acta Biochim. Iran."},{"key":"10.1016\/j.cca.2026.122892_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13010135","article-title":"Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: expanding roles of SGLT2is, GLP-1RAs, and GIP\/GLP-1RAs","volume":"13","author":"Theodorakis","year":"2025","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.cca.2026.122892_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/biom15020213","article-title":"From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework","volume":"15","author":"Theodorakis","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.cca.2026.122892_bb0050","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.cca.2021.10.018","article-title":"The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases","volume":"523","author":"Vural","year":"2021","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.cca.2026.122892_bb0055","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cca.2026.122892_bb0060","series-title":"Environmental Toxicants and Lifestyle Diseases","first-page":"377","article-title":"Interactions between Genetic and Environmental Risk Factors in Lifestyle Diseases","author":"Ali","year":"2025"},{"key":"10.1016\/j.cca.2026.122892_bb0065","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3389\/fendo.2018.00582","article-title":"Environmental pollutants and metabolic disorders: the multi-exposure scenario of life","volume":"9","author":"Le Magueresse-Battistoni","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.cca.2026.122892_bb0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pharmthera.2015.03.005","article-title":"Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability","volume":"151","author":"Clarke","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0075","first-page":"565","article-title":"P4 medicine: how systems medicine will transform the healthcare sector and society","volume":"10","author":"Flores","year":"2013","journal-title":"Perinat. Med."},{"issue":"7","key":"10.1016\/j.cca.2026.122892_bb0080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12032-025-02817-y","article-title":"Precision oncology: transforming cancer care through personalized medicine","volume":"42","author":"Rituraj","year":"2025","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.cca.2026.122892_bb0085","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/HEP.0000000000000786","article-title":"Molecular mechanisms in MASLD\/MASH-related HCC","volume":"82","author":"Wang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cca.2026.122892_bb0090","doi-asserted-by":"crossref","DOI":"10.2174\/0113816128402252251005215721","article-title":"Advancements in personalized medicine for Leukemia: integrating genetic, transcriptomic, and artificial intelligence insights","author":"Raoufinia","year":"2025","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cca.2026.122892_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119686","article-title":"Precision medicine in colorectal cancer: leveraging multi-omics, spatial omics, and artificial intelligence","volume":"559","author":"Xu","year":"2024","journal-title":"Clin. Chim. Acta"},{"issue":"15","key":"10.1016\/j.cca.2026.122892_bb0100","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3748\/wjg.v24.i15.1601","article-title":"Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity","volume":"24","author":"Pirola","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2026.122892_bb0105","article-title":"The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease","volume":"111S","author":"Perakakis","year":"2020","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.cca.2026.122892_bb0110","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrclinonc.2010.227","article-title":"Predictive, personalized, preventive, participatory (P4) cancer medicine","volume":"8","author":"Hood","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cca.2026.122892_bb0115","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3350\/cmh.2021.0127","article-title":"Recent advances in nonalcoholic fatty liver disease metabolomics","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"issue":"11","key":"10.1016\/j.cca.2026.122892_bb0120","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.cgh.2024.05.052","article-title":"Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update","volume":"22","author":"Sookoian","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.cca.2026.122892_bb0125","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3350\/cmh.2020.0136","article-title":"Precision medicine in nonalcoholic fatty liver disease: new therapeutic insights from genetics and systems biology","volume":"26","author":"Sookoian","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.cca.2026.122892_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2024.112866","article-title":"siRNA-mediated gene silencing for non-alcoholic fatty liver disease: a comprehensive review of molecular targets","volume":"208","author":"Mahmoudi","year":"2024","journal-title":"Eur. Polym. J."},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0135","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40001-024-01708-8","article-title":"Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches","volume":"29","author":"Mahmoudi","year":"2024","journal-title":"Eur. J. Med. Res."},{"issue":"12","key":"10.1016\/j.cca.2026.122892_bb0140","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0145","article-title":"Kurbasic, predicting and elucidating the etiology of fatty liver disease: a machine learning modeling and validation study in the IMI","volume":"17","author":"Atabaki-Pasdar","year":"2020","journal-title":"DIRECT cohorts"},{"issue":"4","key":"10.1016\/j.cca.2026.122892_bb0150","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0155","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41588-022-01078-z","article-title":"A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation","volume":"54","author":"Vujkovic","year":"2022","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0160","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cgh.2022.01.015","article-title":"Performance of noninvasive tests of fibrosis among Asians, Hispanic, and non-Hispanic whites in the STELLAR trials","volume":"21","author":"Wong","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.122892_bb0165","first-page":"S19","article-title":"Gender differences in nonalcoholic fatty liver disease","volume":"12","author":"Nagral","year":"2022","journal-title":"Euroasian J. Hepato-Gastroenterol."},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0170","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s12325-017-0556-1","article-title":"NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk","volume":"34","author":"Ballestri","year":"2017","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0175","article-title":"Precision non-alcoholic fatty liver disease (NAFLD) diagnosis: leveraging ensemble machine learning and gender insights for cost-effective detection","volume":"11","author":"Alizargar","year":"2024","journal-title":"Bioengineering (Basel)"},{"issue":"7","key":"10.1016\/j.cca.2026.122892_bb0180","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/liv.15910","article-title":"Sex differences in mortality and liver-related events in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"44","author":"Zhou","year":"2024","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0185","first-page":"83","article-title":"Sex disparity in hepatocellular carcinoma owing to NAFLD and non-NAFLD etiology: epidemiological findings and pathobiological mechanisms","volume":"6","author":"Lonardo","year":"2020","journal-title":"Hepatoma Res."},{"key":"10.1016\/j.cca.2026.122892_bb0190","article-title":"A machine learning based framework to identify and classify non-alcoholic fatty liver disease in a large-scale population","author":"Ji","year":"2022","journal-title":"Front. Public Health Volume 10\u20132022"},{"issue":"3","key":"10.1016\/j.cca.2026.122892_bb0195","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/oby.23960","article-title":"Noninvasive tests to identify liver fibrosis in metabolic dysfunction-associated steatotic liver disease are affected by race","volume":"32","author":"Bril","year":"2024","journal-title":"Obesity"},{"key":"10.1016\/j.cca.2026.122892_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1450317","article-title":"Advancing non-alcoholic fatty liver disease prediction: a comprehensive machine learning approach integrating SHAP interpretability and multi-cohort validation","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.cca.2026.122892_bb0205","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ajhg.2024.03.003","article-title":"Guidance on use of race, ethnicity, and geographic origin as proxies for genetic ancestry groups in biomedical publications","volume":"111","author":"Feero","year":"2024","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0210","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.cca.2026.122892_bb0215","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.cca.2026.122892_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067203","article-title":"Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III","volume":"12","author":"Carrillo-Larco","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.cca.2026.122892_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.120038","article-title":"Navigating liver health with metabolomics: A comprehensive review","volume":"566","author":"Singh","year":"2025","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.cca.2026.122892_bb0230","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1007\/s10753-024-02164-6","article-title":"Multiple machine learning identifies key gene PHLDA1 suppressing NAFLD progression","volume":"48","author":"Yang","year":"2025","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0235","article-title":"Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis","volume":"6","author":"Saldarriaga","year":"2024","journal-title":"JHEP Rep"},{"issue":"23","key":"10.1016\/j.cca.2026.122892_bb0240","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.2174\/0929867330666230516123028","article-title":"Microarray-based detection of critical overexpressed genes in the progression of hepatic fibrosis in non-alcoholic fatty liver disease: A protein-protein interaction network analysis","volume":"31","author":"Mahmoudi","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.cca.2026.122892_bb0245","first-page":"758","article-title":"NIS2+\u2122, An optimisation of the blood-based biomarker NIS4\u00ae technology for the detection of at-risk NASH: a prospective derivation and validation study","volume":"79","author":"Harrison","year":"2023"},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0250","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","article-title":"Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF)","volume":"79","author":"Noureddin","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0255","first-page":"4564","article-title":"Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD","volume":"15","author":"Verschuren","year":"2024"},{"issue":"7","key":"10.1016\/j.cca.2026.122892_bb0260","first-page":"6380","article-title":"Obesity, metabolism, large-scale plasma proteomics improves prediction of major adverse liver outcomes in individuals with MASLD","volume":"28","author":"Yu","year":"2026"},{"issue":"5","key":"10.1016\/j.cca.2026.122892_bb0265","article-title":"Association of per-and polyfluoroalkyl substance exposure with fatty liver disease risk in US adults","volume":"5","author":"Zhang","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.cca.2026.122892_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2024.123937","article-title":"Association between per-and poly-fluoroalkyl substances and nonalcoholic fatty liver disease: a nested case-control study in northwest China","volume":"350","author":"Wu","year":"2024","journal-title":"Environ. Pollut."},{"key":"10.1016\/j.cca.2026.122892_bb0275","article-title":"Associations of urinary organophosphate esters metabolites and diet quality with nonalcoholic\/metabolic dysfunction-associated fatty liver diseases in adults","volume":"254","author":"Aimuzi","year":"2023"},{"issue":"3","key":"10.1016\/j.cca.2026.122892_bb0280","article-title":"DNA methylation and target gene expression in fatty liver progression from simple steatosis to advanced fibrosis","volume":"45","author":"Li","year":"2025"},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0285","article-title":"Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration","volume":"17","author":"Van Dijck","year":"2025"},{"issue":"3","key":"10.1016\/j.cca.2026.122892_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115350","article-title":"Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD","volume":"44","author":"Li","year":"2025","journal-title":"Cell Rep."},{"issue":"18","key":"10.1016\/j.cca.2026.122892_bb0295","first-page":"1435","article-title":"Circulating histones as potential biomarkers of MASLD-MASH-HCC progression","volume":"17","author":"Tsoneva","year":"2025"},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0300","first-page":"117","article-title":"Multicenter collaborative study to optimize mass spectrometry workflows of clinical specimens","volume":"23","author":"Kardell","year":"2023"},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0305","first-page":"1229","article-title":"A generative AI framework unifies human multi-omics to model aging, metabolic health, and intervention response","volume":"38","author":"Chen","year":"2026"},{"key":"10.1016\/j.cca.2026.122892_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465230","article-title":"Validation of two LCHRMS methods for large-scale untargeted metabolomics of serum samples: strategy to establish method fitness-for-purpose","volume":"1732","author":"Grijseels","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"12","key":"10.1016\/j.cca.2026.122892_bb0315","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.cca.2026.122892_bb0320","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cca.2026.122892_bb0325","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2096161","article-title":"Circulating miRNAs as novel diagnostic biomarkers in nonalcoholic fatty liver disease: a systematic review and meta-analysis","author":"Cai","year":"2019","journal-title":"Can. J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.cca.2026.122892_bb0330","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.23050","article-title":"Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study","volume":"50","author":"Feldstein","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cca.2026.122892_bb0335","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211062807","article-title":"Application of artificial intelligence in non-alcoholic fatty liver disease and liver fibrosis: a systematic review and meta-analysis","volume":"14","author":"Decharatanachart","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"10","key":"10.1016\/j.cca.2026.122892_bb0340","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.4254\/wjh.v13.i10.1417","article-title":"Machine learning models for predicting non-alcoholic fatty liver disease in the general United States population: NHANES database","volume":"13","author":"Atsawarungruangkit","year":"2021","journal-title":"World J. Hepatol."},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0345","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12967-025-06387-5","article-title":"Machine learning models for predicting metabolic dysfunction-associated steatotic liver disease prevalence using basic demographic and clinical characteristics","volume":"23","author":"Zhu","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0350","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-026-02163-x","article-title":"Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: evidence from two observational studies","volume":"26","author":"Wu","year":"2026","journal-title":"Clin. Exp. Med."},{"issue":"7","key":"10.1016\/j.cca.2026.122892_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12071026","article-title":"Machine-learning algorithm for predicting fatty liver disease in a Taiwanese population","volume":"12","author":"Chen","year":"2022","journal-title":"J. Pers. Med."},{"issue":"7","key":"10.1016\/j.cca.2026.122892_bb0360","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.gastha.2024.06.007","article-title":"Use of machine learning to predict onset of NAFLD in an all-comers cohort-development and validation in 2 large Asian cohorts","volume":"3","author":"Lim","year":"2024","journal-title":"Gastro Hep Adv"},{"issue":"12","key":"10.1016\/j.cca.2026.122892_bb0365","article-title":"Application of quantitative ultrasonography and artificial intelligence for assessing severity of fatty liver: A pilot study","volume":"14","author":"Kwon","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.cca.2026.122892_bb0370","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1148\/radiol.2020191160","article-title":"Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat with radiofrequency ultrasound data using one-dimensional convolutional neural networks","volume":"295","author":"Han","year":"2020","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0375","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12880-023-01172-6","article-title":"Image-based AI diagnostic performance for fatty liver: a systematic review and meta-analysis","volume":"23","author":"Zhao","year":"2023","journal-title":"BMC Med. Imaging"},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0380","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232442","article-title":"Advancing AI-assisted US screening for fatty liver","volume":"309","author":"Tuthill","year":"2023","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0385","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1007\/s00261-025-05317-9","article-title":"Physics-aware imaging AI for quantitative MASLD biomarker mapping: a systematic review of deep learning and radiomics across ultrasound, CT, and MRI","volume":"51","author":"Maghsoudi","year":"2026","journal-title":"Abdom Radiol (NY)"},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0390","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/cld.1071","article-title":"Artificial intelligence in nonalcoholic fatty liver disease: A new frontier in diagnosis and treatment","volume":"17","author":"Aggarwal","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0395","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-024-03301-2","article-title":"Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Pulaski","year":"2025","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.cca.2026.122892_bb0400","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/jgh.15415","article-title":"Artificial intelligence in precision medicine in hepatology","volume":"36","author":"Su","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0405","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s12876-025-04120-6","article-title":"Machine learning survival models for non-alcoholic fatty liver disease based on a health checkup cohort","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Gastroenterol."},{"issue":"2","key":"10.1016\/j.cca.2026.122892_bb0410","article-title":"Diagnostic of fatty liver using radiomics and deep learning models on non-contrast abdominal CT","volume":"20","author":"Zhang","year":"2025","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cca.2026.122892_bb0415","first-page":"135","article-title":"Transfer learning with pre-trained deep convolutional neural networks for the automatic assessment of liver steatosis in ultrasound images","volume":"23","author":"Constantinescu","year":"2021","journal-title":"Med. Ultrason."},{"issue":"21","key":"10.1016\/j.cca.2026.122892_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38848","article-title":"A machine learning-based predictive model discriminates nonalcoholic steatohepatitis from nonalcoholic fatty liver disease","volume":"10","author":"Yan","year":"2024","journal-title":"Heliyon"},{"issue":"12","key":"10.1016\/j.cca.2026.122892_bb0425","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000578","article-title":"Biological and clinical role of TREM2 in liver diseases","volume":"8","author":"Ma","year":"2024","journal-title":"Hepatol. Commun."},{"issue":"20","key":"10.1016\/j.cca.2026.122892_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/nu14204344","article-title":"Effect of curcumin on attenuation of liver cirrhosis via genes\/proteins and pathways: A system pharmacology study","volume":"14","author":"Mahmoudi","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.cca.2026.122892_bb0435","doi-asserted-by":"crossref","first-page":"3654660","DOI":"10.1155\/2021\/3654660","article-title":"Target deconvolution of fenofibrate in nonalcoholic fatty liver disease using bioinformatics analysis","volume":"2021","author":"Mahmoudi","year":"2021","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.cca.2026.122892_bb0440","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/0113892029280454240214072212","article-title":"Effect of calebin-A on critical genes related to NAFLD: A protein-protein interaction network and molecular docking study","volume":"25","author":"Mahmoudi","year":"2024","journal-title":"Curr. Genomics"},{"issue":"7","key":"10.1016\/j.cca.2026.122892_bb0445","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2174\/0929867331666230829164832","article-title":"Statins as a potential treatment for non-alcoholic fatty liver disease: target deconvolution using protein-protein interaction network analysis","volume":"32","author":"Mahmoudi","year":"2025","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0450","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","article-title":"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials","volume":"83","author":"Armisen","year":"2025","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.cca.2026.122892_bb0455","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jhep.2025.05.031","article-title":"Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis","volume":"83","author":"Sanyal","year":"2025","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0460","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.cca.2026.122892_bb0465","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of Semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0470","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/jgh.12656","article-title":"PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease","volume":"30","author":"Shen","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.cca.2026.122892_bb0475","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cct.2014.02.002","article-title":"Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]","volume":"37","author":"Scorletti","year":"2014","journal-title":"Contemp. Clin. Trials"},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0480","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2015.07.036","article-title":"Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial","volume":"63","author":"Scorletti","year":"2015","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.cca.2026.122892_bb0485","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.cca.2026.122892_bb0490","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.cca.2026.122892_bb0495","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16119","article-title":"Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care","volume":"45","author":"Younossi","year":"2025","journal-title":"Liver Int."},{"issue":"11","key":"10.1016\/j.cca.2026.122892_bb0500","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.42750","article-title":"Cost-effectiveness of MASH diagnosis and management approaches among those with type 2 diabetes","volume":"8","author":"Lazarus","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.cca.2026.122892_bb0505","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s43856-025-00796-9","article-title":"Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial","volume":"5","author":"Shumbayawonda","year":"2025","journal-title":"Commun. Med. (Lond.)"},{"issue":"2","key":"10.1016\/j.cca.2026.122892_bb0510","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10916-020-01693-5","article-title":"Non-alcoholic fatty liver and liver fibrosis predictive analytics: risk prediction and machine learning techniques for improved preventive medicine","volume":"45","author":"Goldman","year":"2021","journal-title":"J. Med. Syst."},{"key":"10.1016\/j.cca.2026.122892_bb0515","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.metabol.2018.08.002","article-title":"Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics","volume":"87","author":"Perakakis","year":"2018","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.cca.2026.122892_bb0520","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/hep.31603","article-title":"Application of artificial intelligence for the diagnosis and treatment of liver diseases","volume":"73","author":"Ahn","year":"2021","journal-title":"Hepatology"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126020747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126020747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:06:45Z","timestamp":1791986805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126020747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":104,"alternative-id":["S0009898126020747"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.122892","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine in MASLD: Integrating genetics, multi-omics, and artificial intelligence for risk stratification and targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.122892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122892"}}